These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1614061)

  • 1. Are calcium antagonists of value in ameliorating the course of chronic renal disease?
    Luft FC; Johnston CI
    Kidney Int Suppl; 1992 May; 36():S114-8. PubMed ID: 1614061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypertension in chronic renal insufficiency.
    Locatelli F; Manzoni C; Marcelli D
    J Nephrol; 1997; 10(4):220-3. PubMed ID: 9377731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension with co-existing renal disease.
    Bauer JH; Reams GP
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():27-34. PubMed ID: 2090835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of calcium antagonists with special reference to manidipine hydrochloride.
    Rodicio JL
    Blood Press Suppl; 1996; 5():10-5. PubMed ID: 8973787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Converting enzyme inhibitors and calcium antagonists in the long-term treatment of hypertension in chronic renal failure.
    Lenz T; August P
    Wien Klin Wochenschr; 1990 May; 102(11):315-9. PubMed ID: 2195780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium antagonists and renal failure progression.
    Robles NR
    Ren Fail; 2008; 30(3):247-55. PubMed ID: 18350443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension and progression of renal insufficiency.
    Fournier A; el Esper N; Makdassi R; Hué P; Westeel PF; Achard JM; Lalau JD
    Nephrol Dial Transplant; 1994; 9 Suppl 3():28-34. PubMed ID: 8072721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypertension and chronic renal insufficiency--chronic kidney failure].
    Monhart V
    Vnitr Lek; 2003 May; 49(5):388-94. PubMed ID: 12908174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protection with the calcium antagonists.
    Neumayer HH; Kunzendorf U
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S11-8. PubMed ID: 1723449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
    Bailey RR; Shand BI; Smith AH; Robson RA; Lynn KL
    Clin Nephrol; 1997 Oct; 48(4):224-9. PubMed ID: 9352156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1995; 2():108-12. PubMed ID: 7582066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?
    Segura J; García-Donaire JA; Ruilope LM
    Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):422-6. PubMed ID: 17693756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.